Kidney Week 2023 Preview

CE / CME

An Expert’s Guide to Kidney Week 2023: A Preview of the Top Abstracts on IgAN

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: November 01, 2023

Expiration: October 31, 2024

Pietro Canetta
Pietro Canetta, MD, MS

Activity

Progress
1
Course Completed

During the 2023 American Society of Nephrology Kidney Week, exciting and important results from many clinical trials will be reported. In this commentary, nephrology experts highlight the abstracts they are most looking forward to seeing presented at the meeting. We will cover these abstracts in more detail as part of Clinical Care Options’ (CCO) Independent Conference Coverage of Kidney Week 2023. As the meeting unfolds, remember to check the CCO website for downloadable slidesets, including the data from these highlighted studies. After the conference, review the expert analysis ClinicalThought commentaries with perspectives and clinical implications of these new data.

Top Picks:
Richard Lafayette, MD, and Pietro Canetta, MD, identified several studies with the potential to change practice including the following:

  • eGFR Decline in Patients With IgA Nephropathy Treated with Nefecon or Placebo: Results From the 2-Year NefIgArd Phase 3 Trial (Abstract TH-OR26)
  • An Open-Label Trial Evaluating the Safety and Efficacy of Budesonide in Patients With IgA Nephropathy at High Risk of Progression (Abstract SA-PO891)
  • Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases (Abstract SA–OR84)
  • Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE) (Abstract SA-PO903)
  • From Famine to Feast in IgA Nephropathy: New Treatments Present New Opportunities for Patients (Abstract SA-PO905)
  • Further Insights Into Iptacopan Mode of Action in IgA Nephropathy Through Protein Profiling (Abstract FR-PO706
  • Identification of Noninvasive Biomarkers Reflecting Cellular Mechanisms of Endothelin A (ETA) Receptor Activity and Atrasentan Response in CKD (Abstract TH-OR16)

Remember to Check the CCO Website Often During and After Kidney Week!
Downloadable slideset summaries of these key studies will be available on the CCO website as the data are released.

Poll

1.

Which of the following abstracts are you most looking forward to seeing presented at Kidney Week 2023?

Submit